Tag : OVARIAN CANCER

The use of primary cytoreductive surgery (PCS) for ovarian cancer has declined over the past decade, from 70% in 2010 to 37% in 2021, as neoadjuvant chemotherapy (NACT) emerged as an alternative to optimize surgical outcomes and reduce perioperative morbidity.

Poly (ADP-ribose)-polymerase inhibitors (PARPis) like olaparib have transformed the treatment landscape for high-grade serous ovarian cancer, with multiple trials showing significant improvement in progression-free survival (PFS). Although PFS benefits with PARPis appear to be consistent in patient

Thrombocytosis is frequently observed among cancer patients and can be attributed to increased platelet production. While the underlying pathophysiology has not been completely elucidated, it is believed that platelet activation is essential for tumor progression due to the release of several platelet-derived growth factors that can promote cellular proliferation, neo-vascularization, and ultimately tumor growth, tissue invasion, and metastasis.

Ovarian cancer remains the most deadly gynecologic malignancy, and its incidence has been steadily increasing over the past few decades. In Hong Kong, ovarian cancer is the 7th leading cause of female cancer deaths. The crude death rate was 5.5 per 100,000 female population. In 2017, a total of 218 women died from this cancer, accounting for 3.7% of all cancer deaths in females. In a recent interview, Dr. William Foo, Specialist in Clinical Oncology, shared his insights on the management of ovarian cancer in Hong Kong.